Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
| ▸ | NMT1 | P30419 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3669421 | 0.80 | BACE1 (0.44) | CYP2A6PDE3BPDE3AALDH1A1CYP1A2 | |
| SCHEMBL10078327 | 0.79 | CYP2A6 (0.47) | CYP2A6PDE3BPDE3AKDM4ECCR1 | |
| SCHEMBL10131797 | 0.79 | LMNA (0.46) | KDM4ECYP3A4CYP2C19HIF1AIDO1 | |
| SCHEMBL19044341 | 0.76 | CYP2A6 (0.44) | CYP2A6PDE3BPDE3AKDM4ECYP3A4 | |
| SCHEMBL21481038 | 0.74 | CYP2A6 (0.42) | CYP2A6PDE3BPDE3AKDM4ECYP3A4 | |
| SCHEMBL3320611 | 0.72 | POLB (0.47) | KDM4ECYP3A4CYP2C19HIF1AALDH1A1 | |
| SCHEMBL2312719 | 0.72 | ADORA2A (0.46) | PDE3BPDE3AKDM4ECYP2C19HIF1A | |
| SCHEMBL13853234 | 0.72 | CYP2A6 (0.40) | CYP2A6PDE3BPDE3AKDM4EMAPT | |
| SCHEMBL16677113 | 0.71 | CYP2A6 (0.47) | CYP2A6PDE3BPDE3AKDM4ECYP3A4 | |
| SCHEMBL12083607 | 0.70 | PDE3B (0.40) | CYP2A6PDE3BPDE3AALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828985-B2 | Carbamate and urea inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20130244994-A1 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | CLAREMON DAVID A (US) | 2013-09-19 | — | — | US | disclosed |
| US-8399504-B2 | Carbamate and urea inhibitors of 11Beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8258301-B2 | Urotensin II receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| US-8258301-B2 | Urotensin II receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| US-8258301-B2 | Urotensin II receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| CN-101506165-B | Phenyl, pyridine and quinoline derivatives | HOFFMANN LA ROCHE | 2012-07-04 | — | — | CN | disclosed |
| US-20110112062-A1 | Carbamate And Urea Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | VITAE PHARMACEUTICALS, INC | 2011-05-12 | — | — | US | disclosed |
| EP-2276730-A2 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20100121051-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-13 | — | — | US | disclosed |
| US-20100121051-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-13 | — | — | US | disclosed |
| US-20100121051-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-13 | — | — | US | disclosed |
| EP-2155748-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2010-02-24 | — | — | EP | disclosed |
| WO-2009131669-A2 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| CN-101506165-A | Phenyl, pyridine and quinoline derivatives | HOFFMANN LA ROCHE (CH) | 2009-08-12 | — | — | CN | disclosed |
| WO-2008144268-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008144268-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-27 | — | — | WO | disclosed |
| EP-0446604-A2 | Pyridine and related aza heterocycle derivatives as cardiovascular agents | AMERICAN CYANAMID COMPANY (US) | 1991-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244994-A1 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD3B1, HSD17B1 | CYP2A6 226/4885PDE3B 117/4885PDE3A 147/4885 |
| US-20100121051-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, AGTR1, AGTR2 | CYP2A6 2436/4885PDE3B 2879/4885PDE3A 2180/4885 |
| US-20110112062-A1 | Carbamate And Urea Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD3B1, HSD17B1 | CYP2A6 76/4885PDE3B 159/4885PDE3A 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.